Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

References

• ThomasALiuSVSubramaniamDSGiacconeGRefining the treatment of NSCLC according to histological and molecular subtypesNat Rev Clin Oncol201512951152625963091
   PubMed Web of Science ®Google Scholar
• DeSantisCELinCCMariottoABCancer treatment and survivorship statistics, 2014CA Cancer J Clin201464425227124890451
   PubMed Web of Science ®Google Scholar
• SteuerCERamalingamSSTargeting EGFR in lung cancer: lessons learned and future perspectivesMol Aspects MedIn press2015
   Web of Science ®Google Scholar
• MorrisSWKirsteinMNValentineMBFusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphomaScience19942635151128112848122112
   PubMed Web of Science ®Google Scholar
• SolomonBVarella-GarciaMCamidgeDRALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerJ Thorac Oncol20094121450145420009909
   PubMed Web of Science ®Google Scholar
• HoutmanSHRuttemanMDe ZeeuwCIFrenchPJEchinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubulesNeuroscience200714441373138217196341
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Natl Acad Sci U S A200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• InamuraKTakeuchiKTogashiYEML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onsetMod Pathol200922450851519234440
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuSHALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res201319154273428123729361
   PubMed Web of Science ®Google Scholar
• SolomonBWilnerKDShawATCurrent status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancerClin Pharmacol Ther2014951152324091716
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
   PubMed Web of Science ®Google Scholar
• ShawATEngelmanJAALK in lung cancer: past, present, and futureJ Clin Oncol20133181105111123401436
   PubMed Web of Science ®Google Scholar
• GridelliCPetersSSgambatoACasaluceFAdjeiAACiardielloFALK inhibitors in the treatment of advanced NSCLCCancer Treat Rev201440230030623931927
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• FramptonJECrizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancerDrugs201373182031205124288180
   PubMed Web of Science ®Google Scholar
• CuiJJTran-DubéMShenHStructure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymalepithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Med Chem201154186342636321812414
   PubMed Web of Science ®Google Scholar
• O’BryantCLWengerSDKimMThompsonLACrizotinib: a new treatment option for ALK-positive non-small cell lung cancerAnn Pharmacother201347218919723386065
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther200763314332218089725
   PubMed Web of Science ®Google Scholar
• GandhiLJännePACrizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new targetClin Cancer Res201218143737374222547770
   PubMed Web of Science ®Google Scholar
• SasakiTJännePANew strategies for treatment of ALK-rearranged non-small cell lung cancersClin Cancer Res201117237213721822010214
   PubMed Web of Science ®Google Scholar
• CurranMPCrizotinib: in locally advanced or metastatic non-small cell lung cancerDrugs20127219910722191798
   PubMed Web of Science ®Google Scholar
• HamiltonGRathBBurghuberOPharmacokinetics of crizotinib in NSCLC patientsExpert Opin Drug Metab Toxicol201511583584225732197
   PubMed Web of Science ®Google Scholar
• KozloffMFMartinLPKrzakowskiMPharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumorsJ Clin Oncol201129supple13065
   Google Scholar
• NiuFYWuYLPersonalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinibOnco Targets Ther20158999100725999733
   PubMed Web of Science ®Google Scholar
• NarayananVHonceMJMehrotraSCamidgeDRCystic brain metastases occurring in anaplastic lymphoma kinase gene rearranged non-small-cell lung cancer patients receiving crizotinibClin Lung Cancer Epub2015730
   Web of Science ®Google Scholar
• CostaDBShawATOuSHClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
   PubMed Web of Science ®Google Scholar
• CostaDBKobayashiSPandyaSSCSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibJ Clin Oncol201129e443e44521422405
   PubMed Web of Science ®Google Scholar
• CameronLSolomonBNew treatment options for ALK-rearranged non-small cell lung cancerCurr Treat Options Oncol20151610367
   Web of Science ®Google Scholar
• AwadMMShawATALK inhibitors in non-small cell lung cancer: crizotinib and beyondClin Adv Hematol Oncol201412742943925322323
   PubMedGoogle Scholar
• ZouHYFribouletLKodackDPPF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical modelsCancer Cell2015281708126144315
   PubMed Web of Science ®Google Scholar
• OuSHCrizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondDrug Des Devel Ther20115471485
   PubMed Web of Science ®Google Scholar
• RothschildSIGautschiOCrizotinib in the treatment of non-small-cell lung cancerClin Lung Cancer201314547348023790969
   PubMed Web of Science ®Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927suppl148s
   Google Scholar
• LazzariCSpitaleriGCataniaCTargeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic optionsCrit Rev Oncol Hematol201489335836524156959
   PubMed Web of Science ®Google Scholar
• IaconoDChiariRMetroGFuture options for ALK-positive non-small cell lung cancerLung Cancer201587321121925601484
   PubMed Web of Science ®Google Scholar
• KanaanZKloeckerGHPaintalAPerezCANovel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyondOnco Targets Ther2015888589225945060
   PubMed Web of Science ®Google Scholar
• CrinòLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE1005J Clin Oncol201129suppl7514
   Web of Science ®Google Scholar
• KimDAhnMShiYUpdated results of a global phase II study with crizotinib in advanced ALK positive NSCLCAnn Oncol201223suppl 9402
   Google Scholar
• OuSHBartlettCHMino-KenudsonMCuiJIafrateAJCrizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyOncologist201217111351137522989574
   PubMed Web of Science ®Google Scholar
• ToyokawaGSetoTALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Clin Lung Cancer201415531331924984564
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• ShawATOuSHBangYJCrizotinib in ROS1-rearranged non–small-cell lung cancerN Engl J Med2014371211963197125264305
   PubMed Web of Science ®Google Scholar
• PaillerEAugerNLindsayCRHigh level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerAnn Oncol20152671408141525846554
   PubMed Web of Science ®Google Scholar
• SchefflerMSchultheisATeixidoCROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityOncotarget2015612105771058525868855
   PubMedGoogle Scholar
• ChoiYLSodaMYamashitaYALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A2011108187535754021502504
   PubMed Web of Science ®Google Scholar
• OkamotoINakagawaKEchinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspectsCancer Sci201210381391139622568572
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• NishioMMurakamiHHoriikeAPhase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumorsJ Thorac Oncol20151071058106626020125
   PubMed Web of Science ®Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 studyLancet Oncol201314759059823639470
   PubMed Web of Science ®Google Scholar
• ToyokawaGSetoTTakenoyamaMIchinoseYInsights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Cancer Metastasis Rev Epub201595
   PubMed Web of Science ®Google Scholar
• LiaoBCLinCCShihJYYangJCTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyTher Adv Med Oncol20157527429026327925
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• PillaiRNRamalingamSSHeat shock protein 90 inhibitors in non-small-cell lung cancerCurr Opin Oncol201426215916424463348
   PubMed Web of Science ®Google Scholar